Head of the department- hematologist of the Day Hospital of Hematology and Chemotherapy of Plasma Cell Tumors
Candidate of Medical Sciences, hematologist of the highest qualification category
Maya Solovieva graduated from the I.M. Sechenov First Moscow State Medical University and was awarded the qualification of a doctor in the specialty "General Medicine" (2012). She studied in clinical residency from 2012-2014 and in full-time postgraduate studies at the Department of Intensive High-dose Chemotherapy of Paraproteinemic Hemoblastoses of NMRC for Hematology in the specialty "hematology and blood transfusion" (2014 - 2017). She defended her thesis for the degree of Candidate of Medical Sciences (2017) on the topic "Clinical and morphological characteristics and molecular biological features of the tumor substrate in patients with multiple myeloma occurring with plasmocytoma" (heads: Doctor of Medical Sciences, Prof. L.P. Mendeleeva and Doctor of Biological Sciences, A.M. Kovrigina).
Researcher (2018 – 2020), Senior Researcher (from 2020 to the present) of the Department of Chemotherapy of Paraproteinemic Hemoblastoses. In 2022, she became the head of the newly organized Day Hospital of Hematology and Chemotherapy of Plasma Cell Tumors.
Solovieva is a highly skilled hematologist and an expert in all methods of diagnosis and treatment of plasma cell tumors. She regularly participates as a speaker at scientific congresses and scientific-practical conferences, webinars, and seminars. She is an active participant in the educational process, being the head of a Candidate of Medical Sciences thesis and mentor of young doctors and residents. She develops educational programs on topical issues of clinical hematology and is the coordinator of several international and Russian clinical studies on the efficacy and safety of the latest drugs for the treatment of multiple myeloma.
The scientific research carried out by Solovieva is devoted to the study of the molecular biological basis of the pathogenesis of multiple myeloma, solitary plasmacytoma, extramedullary lesions; the development of protocols, standards and algorithms for the diagnosis and treatment of these diseases.
She has published more than 120 scientific publications.
